Award
National Cancer Institute 5R21CA288928-02
Mechanisms of Th17-DC immunotherapy for ovarian cancer
Recipient
National Cancer Institute (NCI)
Award Amount
$178,819.00
Ceiling
$178,819.00
Awarded
February 14, 2025
Identifier
5R21CA288928-02
Research project funded by the National Cancer Institute to study the mechanisms of Th17-DC immunotherapy for ovarian cancer, focusing on the role of B cells and tertiary lymphoid structures in treatment efficacy.
Description
The project involves research on Th17-DC immunotherapy for ovarian cancer, testing the hypothesis that its efficacy depends on host B cell responses. The project is funded by the NIH, with a focus on immunotherapy, ovarian cancer, and translational research. The project includes specific aims to evaluate B cell roles and tertiary lymphoid structures in treatment response.